# SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

> **NCT06804161** · PHASE3 · RECRUITING · sponsor: **Prof. Dr. med. Ingo Eitel** · enrollment: 3000 (estimated)

## Conditions studied

- Atrial Hypertension

## Interventions

- **DRUG:** SGLT2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06804161
- **Lead sponsor:** Prof. Dr. med. Ingo Eitel
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2032-05-30
- **Final completion:** 2032-05-30
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06804161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06804161, "SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06804161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*